

Reviars commnets

A comprehensive well written manuscript on selecting patient with pancreatic adenocarcinoma for genetic predisposition. Use of EUROPAC research criteria in this situation to review potential patients meeting these criteria in a consecutive patients in a single tertiary referral centre and seeing the actual real world experience and reasons for only a small number being screened. As well as established benefits of genetic counselling and surveillance advances in developmental therapeutics mean that germline mutations are potentially druggable. Paper is appropriately supported by tables, figures and the references. The authors make some observations of the challenges of identification and some practice suggestions. Some discussion on on identification and early referral of patients before they deteriorate is present.

Reply: no reply required

A comment on appropriately resourcing of s genetic counselling services and access to genomics would be useful if teh actual numbers who could benefit from screening are referred.

Reply: this has been incorporated

A table to compare the research based EUROPAC guidelines with the referenced clinical guidelines would be useful.

Reply: Our local guidelines are the same as EUROPAC, thus this table does not apply

Reference 6: author list is corrupted.

Reply: reference has been amended